Lipocine Inc. (LPCN)
NASDAQ: LPCN · Real-Time Price · USD
2.060
-0.050 (-2.37%)
Aug 4, 2026, 12:36 PM EDT - Market open
Lipocine Employees
Lipocine had 14 employees as of December 31, 2025. The number of employees decreased by 2 or -12.50% compared to the previous year.
Employees
14
Change (1Y)
-2
Growth (1Y)
-12.50%
Revenue / Employee
$112,104
Profits / Employee
-$846,529
Market Cap
16.98M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 14 | -2 | -12.50% |
| Dec 31, 2024 | 16 | -1 | -5.88% |
| Dec 31, 2023 | 17 | 0 | - |
| Dec 31, 2022 | 17 | 4 | 30.77% |
| Sep 30, 2022 | 17 | 4 | 30.77% |
| Jun 30, 2022 | 15 | 2 | 15.38% |
| Mar 31, 2022 | 13 | 0 | - |
| Dec 31, 2021 | 13 | 2 | 18.18% |
| Sep 30, 2021 | 13 | 2 | 18.18% |
| Jun 30, 2021 | 13 | - | - |
| Mar 31, 2021 | 13 | 1 | 8.33% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Pluri | 142 |
| Celularity | 115 |
| NextCure | 40 |
| Citius Pharmaceuticals | 23 |
| Jasper Therapeutics | 22 |
| NeuroSense Therapeutics | 17 |
| Quantum BioPharma | 17 |
| Atossa Therapeutics | 16 |
LPCN News
- 4 hours ago - Lipocine reports Q2 EPS (32c) vs. (41c) last year - TheFly
- 1 day ago - Lipocine Appoints Michael J. Grissinger to Board of Directors - PRNewsWire
- 7 weeks ago - Lipocine Transcript: KOL event - Transcripts
- 7 weeks ago - Lipocine Slides: KOL event - Filings
- 2 months ago - Lipocine Inc. to Host Virtual KOL Event Highlighting Unmet Needs in Postpartum Depression and the Clinical Profile of LPCN 1154 - PRNewsWire
- 2 months ago - Lipocine Transcript: A.G.P.'s Annual Virtual Healthcare Conference - Transcripts
- 2 months ago - Lipocine Announces LPCN 1154 Phase 3 Data Accepted for Oral Presentation at 2026 ASCP Annual Meeting - PRNewsWire
- 2 months ago - Anaveon Strengthens Leadership Team with Appointments of Eric Zanelli as Chief Scientific Officer and Jill Jene as Chief Business Officer - GlobeNewsWire